Compare EPAM Systems Inc (EPAM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Merck & Co., Inc. — how do they compare? EPAM Systems Inc trades at $100.23 (market cap $5.15B), while Merck & Co., Inc. trades at $132.99 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 62.5× EPAM Systems Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| EPAM | MRK | |
|---|---|---|
Market Cap | $5.15B | $321.77B |
Sector | Technology | Health |
52-Week High | $221.40 | $131.84 |
52-Week Low | $76.04 | $77.60 |
Enterprise Value | $4.52B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $99.00, up 1.67% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 13.55 and P/S of 0.97, while profitability remains solid with a net margin of 7.15%. Recent news highlights strong Q2 2026 earnings but a lowered revenue outlook due to slower North American growth and a new OpenAI partnership.
Outlook is mixed: strong fundamentals and analyst consensus ($117.27 target) support upside, but technical weakness and growth headwinds pose risks. Investment opportunity lies in valuation discount and AI initiatives, countered by demand volatility and competitive pressures.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
